Loading…

Loading grant details…

Active NON-SBIR/STTR RPGS NIH (US)

Testing the Effectiveness of NAFLD Clinical Care Pathway in VA Primary Care


Funder Veterans Affairs
Recipient Organization Michael E Debakey Va Medical Center
Country United States
Start Date Feb 01, 2024
End Date Jan 31, 2028
Duration 1,460 days
Number of Grantees 2
Roles Principal Investigator; Co-Investigator
Data Source NIH (US)
Grant ID 10752764
Grant Description

Background: In the United States, non-alcoholic fatty liver disease (NAFLD) affects 25-30% of adults and has become a leading cause of chronic liver disease including cirrhosis and liver cancer. The burden of NAFLD and its complications among patients in the Department of Veterans Affairs (VA) is increasing. Most complications

occur among patients with advanced hepatic fibrosis. Treatment (e.g., weight loss) improves patients’ outcomes. Significance: Our data indicate that most VA patients with NAFLD are undiagnosed and untreated. There is an urgent need to address this major gap in care. Most people with NAFLD are seen in primary care settings. The

NAFLD Clinical Care Pathway (NCCP) is a multistep, algorithmic process that entails identification of patients at risk through an e-trigger (Step 1), targeted history and lab testing (Step 2), noninvasive testing for hepatic fibrosis using FIB-4 (Step 3), elective additional fibrosis testing with Fibroscan for those with indeterminate FIB-4 (Step

4), and subsequent recommended management. The NCCP has face and content validity based on consensus of multiple stakeholders including VA clinicians, and high efficacy in our preliminary data. We propose to adapt the multicomponent NCCP intervention for use in VA primary care and prospectively test its effectiveness for

identification and severity stratification of patients with NAFLD. Our approach is consistent with VA strategic priorities to implement a more “Veteran-centered” approach that improves access to care. Innovation & Impact: This is the first study to examine the effectiveness of any NAFLD clinical care pathway in

a VA primary care practice. The design is a cluster-randomized controlled trial with randomization at the level of Patient Aligned Care Teams (PACTs) in primary care, and a state-of-the-art technique to diagnose NAFLD and stage the severity of hepatic fibrosis. Our formative and summative evaluation will provide key information about

the feasibility, acceptability and determinants of implementation. The NCCP intervention is a paradigm shift in NAFLD care from haphazard and sporadic care into a systematic, equitable, and evidence-based approach. Specific Aims: Aim 1. Conduct a formative evaluation to assess feasibility and acceptability of the NCCP among

patients and providers; adapt the NCCP for prospective testing based on feedback. Aim 2. Examine the effectiveness of the NCCP intervention compared to usual care in improving NAFLD care processes and patient outcomes. Aim 3. Conduct a summative evaluation to identify patient and provider characteristics associated

with effectiveness of NCCP and to assess future implementation. Our hypothesis is that NCCP when adapted to Patient Aligned Care Teams (PACTs) in VA primary care considerably increases the identification of patients with NAFLD and those with high-risk NAFLD, and results in an increase in guideline-concordant management.

Methodology: The study will be conducted in primary care settings in a single large VA Medical Center. We will conduct patient interviews and focus groups with PACTs to inform adaption of the NCCP. We will then conduct a cluster-randomized trial of 16 PACTs in primary care to compare the effectiveness of NCCP to usual care in

improving NAFLD care, with PACTs as unit of randomization and patients as the unit of analysis. The multicomponent intervention includes an e-trigger to identify patients eligible for NAFLD screening and calculate fibrosis scores, a structured provider education on NAFLD management and treatment recommendations, and

coordination by an interprofessional team. The primary outcome will be a composite binary variable consisting of NAFLD diagnosis and risk stratification. Secondary outcomes include referral to a weight loss program, referral of patients with advanced fibrosis to hepatology specialty care, and enrollment among those referred to weight

loss and hepatology specialty care. Summative evaluation will inform future implementation. Next Steps/Implementation: Our study will provide information needed to support future projects to implement the NCCP in VA primary care settings. The study will also lay the foundation for a subsequent project to examine

the adopted intervention’s effect on weight loss and NAFLD biomarkers in patients with high-risk NAFLD.

All Grantees

Michael E Debakey Va Medical Center

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant